63 reports

Top ## players hold majority of stake in the market ##.

  • Depression
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

You can easily book an appointment with one online.

  • Depression
  • Allergan plc
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

One of the driving factors is the increasing healthcare expenditure, which is influenced by the rise in disposable income.

  • Depression
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.

Global Vaccines, Oncology, and Consumer Healthcare (VOC): Global Vaccines, oncology, and Consumer healthcare (VOC) focuses on development and commercialization of vaccine and products.

  • Depression
  • World
  • AstraZeneca PLC
  • Lundbeck Inc.
  • Pfizer Inc.

IS THE GLOBAL HEAD AND EVP OF HEALTHCARE OPERATIONS AND STRATEGY.

  • Depression
  • Mental Health
  • United States
  • World
  • Forecast

LONG-TERM MENTAL HEALTH CARE FOR PEOPLE WITH SEVERE MENTAL DISORDERS.

  • Depression
  • Alkermes plc
  • Allergan plc
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.

Major Depressive Disorder - Current and Future Players ## Table of Contents ## Table of Contents ## ##. ## List of Tables ## ##. ## List of Figures ## ## Introduction ## ##. ## Related Reports ## ##. ## Upcoming Related Reports ## ## Market Outlook ## ##. ## Global Markets ## ##. ##. ## Forecast ## ##. ##. ## Drivers a

  • Depression
  • Therapy
  • World
  • Company
  • Demand

Healthcare Expenditure (2009-2015) Global Female Population (2010-2015) Global Depressive Disorder Market Revenue Comparison (2015) Global Anti-Depressant Market Share by Drugs (2015) Global Anti-Depressant Drug Revenue Comparison (2018) Global Anti-Psychotic Market Share by Drugs (2015) Gl

  • Antipsychotic
  • Depression
  • Therapy
  • World
  • Forecast

Psychiatry; ##(##): ##-##.

  • Depression
  • Japan
  • United States
  • World
  • Forecast

It is the largest telephone-based healthcare survey in the world.

  • Depression
  • Actavis plc
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • GlaxoSmithKline plc

Major Depressive Disorder - ##EU Drug Forecast and Market Assessment to 2025 ## Table of Contents ## Table of Contents ## ##. ## List of Tables ## ##. ## List of Figures ## ## Introduction ## ##. ## Related Reports ## ##. ## Upcoming Related Reports ## ## Disease Overview ## ##. ## Etiology and Pathophy

  • Depression
  • Mental Health
  • Therapy

Major Depressive Disorder - Japan Drug Forecast and Market Assessment to 2025 ## Table of Contents ## Table of Contents ## ##. ## List of Tables ## ##. ## List of Figures ## ## Introduction ## ##. ## Related Reports ## ##. ## Upcoming Related Reports ## ## Disease Overview ## ##. ## Etiology and Pathop

  • Depression
  • Therapy
  • Japan
  • Demand

Major Depressive Disorder - US Drug Forecast and Market Assessment to 2025 ## Table of Contents ## Table of Contents ## ##. ## List of Tables ## ##. ## List of Figures ## ## Introduction ## ##. ## Related Reports ## ##. ## Upcoming Related Reports ## ## Disease Overview ## ##. ## Etiology and Pathophys

  • Depression
  • Therapy
  • United States

One St.

  • Depression
  • United States
  • GlobalData's company
  • Jude Medical, Inc.
  • Thoratec Corporation

It is the largest telephone-based healthcare survey in the world.

  • Depression
  • United States
  • Actavis plc
  • Eli Lilly & Co.
  • GlaxoSmithKline plc

The company' s deal volume decreased from two pharmaceuticals & healthcare deals in 2016 to one pharmaceuticals & healthcare deal in 2017.

  • Depression
  • Pharmaceutical
  • United States
  • Company
  • RespireRx Pharmaceuticals Inc.

In addition, we expect one of our principal collaborators, the U. S.

  • Depression
  • Healthcare
  • Therapy
  • United States
  • VistaGen Therapeutics, Inc.

The company' s deal volume decreased from two pharmaceuticals & healthcare deals in 2016 to one pharmaceuticals & healthcare deal in 2017.

  • Depression
  • Therapy
  • United States
  • Company Operations
  • SAGE Therapeutics

The company' s deal volume decreased from two pharmaceuticals & healthcare deals in 2016 to one pharmaceuticals & healthcare deal in 2017.

  • Depression
  • Therapy
  • United States
  • Company Financials
  • SAGE Therapeutics

GlobalData Neuralstem Inc' s, deal volume decreased from three pharmaceuticals & healthcare deals in 2016 to one pharmaceuticals & healthcare deal in 2017.

  • Depression
  • United States
  • Company
  • Company Operations
  • Neuralstem, Inc.

It partners with other healthcare industries for researching and assessing the drug effects on cardiac risk.

  • Depression
  • Therapy
  • United States
  • Litigation And Patent
  • VistaGen Therapeutics, Inc.

GlobalData offers comprehensive geographic coverage across world' s most important sectors, focusing particularly on energy and healthcare.

  • Depression
  • Stroke
  • United States
  • Company Financials
  • Nexstim Plc

Increasing prevalence of mental disorders, rapidly changing healthcare sector, and increasing healthcare spending are driving the growth for Asia Pacific depression screening market.

  • Depression
  • North America
  • United States
  • World
  • Demand

In addition, Genomind has been recognized by Modern Healthcare as one of the best places to work and was included in The Philadelphia ##®for being among the ## fastest-growing companies in the region.

  • Depression
  • United States
  • Company
  • Deals & Alliance
  • Genomind, Inc.

Medison provides integrated services for international healthcare companies to expand their presence in Israel and Romanian healthcare markets.

  • Depression
  • Medical Device
  • Israel
  • United States
  • Brainsway Ltd.

MAR ##, 2015: SUVEN LIFE SECURES ONE (##) PRODUCT PATENT EACH IN EURASIA AND ISRAEL The U. S.

  • Depression
  • Psychotic Disorder
  • United States
  • World
  • Product Initiative

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Depression
  • Therapy
  • World
  • Product Initiative
  • Suven Life Sciences Ltd

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Depression
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Depression
  • Psychotic Disorder
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd

IT CAN BE DIFFICULT TO STRIKE THE RIGHT BALANCE OF STIMULATION BECAUSE IF IT S TOO HIGH THE PATIENT WILL BE HYPOMANIC AND IF IT S TOO LOW IT WON T WORK, GOODMAN SAID.

  • Clinical Trial
  • Depression
  • Mental Health
  • Therapy
  • GlobalData's company